Literature DB >> 35064453

A high tumour-stroma ratio (TSR) in colon tumours and its metastatic lymph nodes predicts poor cancer-free survival and chemo resistance.

M T A Strous1,2, T K E Faes3, A L H M Gubbels3, R L A van der Linden4, W E Mesker5, K Bosscha4, C M Bronkhorst6, M L G Janssen-Heijnen7,8, F J Vogelaar9, A P de Bruïne3.   

Abstract

PURPOSE: Despite known high-risk features, accurate identification of patients at high risk of cancer recurrence in colon cancer remains a challenge. As tumour stroma plays an important role in tumour invasion and metastasis, the easy, low-cost and highly reproducible tumour-stroma ratio (TSR) could be a valuable prognostic marker, which is also believed to predict chemo resistance.
METHODS: Two independent series of patients with colon cancer were selected. TSR was estimated by microscopic analysis of 4 µm haematoxylin and eosin (H&E) stained tissue sections of the primary tumour and the corresponding metastatic lymph nodes. Patients were categorized as TSR-low (≤ 50%) or TSR-high (> 50%). Differences in overall survival and cancer-free survival were analysed by Kaplan-Meier curves and cox-regression analyses. Analyses were conducted for TNM-stage I-II, TNM-stage III and patients with an indication for chemotherapy separately.
RESULTS: We found that high TSR was associated with poor cancer-free survival in TNM-stage I-II colon cancer in two independent series, independent of other known high-risk features. This association was also found in TNM-stage III tumours, with an additional prognostic value of TSR in lymph node metastasis to TSR in the primary tumour alone. In addition, high TSR was found to predict chemo resistance in patients receiving adjuvant chemotherapy after surgical resection of a TNM-stage II-III colon tumour.
CONCLUSION: In colon cancer, the TSR of both primary tumour and lymph node metastasis adds significant prognostic value to current pathologic and clinical features used for the identification of patients at high risk of cancer recurrence, and also predicts chemo resistance.
© 2021. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).

Entities:  

Keywords:  Chemo resistance; Colon cancer; Survival; TSR; Tumour stroma ratio

Mesh:

Year:  2022        PMID: 35064453     DOI: 10.1007/s12094-021-02746-y

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  3 in total

1.  Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases.

Authors:  J A McKay; J J Douglas; V G Ross; S Curran; F Y Ahmed; J F Loane; G I Murray; H L McLeod
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

2.  Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene.

Authors:  Katrina M Comerford; Timothy J Wallace; Jörn Karhausen; Nancy A Louis; Michael C Montalto; Sean P Colgan
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

3.  The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage.

Authors:  Wilma E Mesker; Jan M C Junggeburt; Karoly Szuhai; Pieter de Heer; Hans Morreau; Hans J Tanke; Rob A E M Tollenaar
Journal:  Cell Oncol       Date:  2007       Impact factor: 6.730

  3 in total
  1 in total

1.  KIT promotes tumor stroma formation and counteracts tumor-suppressive TGFβ signaling in colorectal cancer.

Authors:  Jamila Laoukili; Onno Kranenburg; Emre Küçükköse; Niek A Peters; Inge Ubink; Veere A M van Keulen; Roxanna Daghighian; André Verheem
Journal:  Cell Death Dis       Date:  2022-07-16       Impact factor: 9.685

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.